Adipotide vs Cagrilintide
Emerging vs Extensively Studied
monitor Researched · 90% No clinical data on co-administration; mechanisms differ.
Molecular Data
Adipotide Cagrilintide
Weight N/A 4,409.01 Da
Half-life Not established ~7 days (159-195 hours)
Chain N/A 37 amino acids
Type Chimeric peptidomimetic Amylin receptor agonist
Key Benefits
Adipotide
01 Rapid fat-mass reduction via selective white adipose tissue vascular targeting
02 Improved insulin sensitivity following adipose reduction
03 Non-CNS peripheral mechanism distinct from appetite suppressants
Cagrilintide
01 FDA development candidate with extensive Phase 3 data
02 Superior weight loss in combination with semaglutide (22.7%)
03 Once-weekly convenience
04 2.2% HbA1c reduction with CagriSema
Dosing Protocols
Adipotide
0.43 mg/kg / Once daily
Primate Research Replication 0.43 mg/kg Once daily
Dose-Finding (Research) 0.10-0.75 mg/kg Once daily (escalating tiers)
Cagrilintide
2.4mg weekly (after escalation) / Once weekly, same day each week
Weight Loss (Monotherapy) 2.4mg Once weekly
Weight Loss (CagriSema) 2.4mg + semaglutide 2.4mg Once weekly
Type 2 Diabetes Management 2.4mg weekly Once weekly
Dose Escalation Protocol 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg Weekly increases over 16 weeks
Side Effects
Adipotide
Mild creatinine elevation
Electrolyte shifts
Dose-dependent proximal tubule changes (reversible in primates)
Cagrilintide
Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Contraindications
Pregnancy/lactation (not studied)
Dehydration
Concurrent nephrotoxic medications
Not recommended in pregnancy or breastfeeding
Not yet commercially available (FDA approval expected Q1 2026)
Research Evidence
Adipotide Cagrilintide
Status Emerging Extensively Studied
References 4 studies 3 studies
Latest — December 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.